1 published article · Updated continuously
7 trials tracked for idiopathic short stature: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 99 citations.
Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Treatment with somatropin has been shown to significantly increase height velocity (Ht-V) compared to placebo, with observed increases of 12.02 and 6.87 respectively (p<0.0001) 3. Similarly, DA-3002 demonstrated an annualized height velocity of 10.68 cm/year versus 5.72 cm/year over a 26-week period 4.
Aromatase Inhibitor treatment resulted in significant increases in height (ranging from 14 to 18.9) with p<0.006, while also showing statistically significant improvements in lean body mass (p=0.015) 1. However, this intervention did not result in a statistically significant change in bone density z-scores adjusted for height (p=0.906) 1.
Saizen® demonstrated a significant increase in height velocity at month 6 compared to placebo (p<0.0001) 2. Clinical evaluations of Genotropin showed no statistically significant difference between treatment arms regarding absolute on-target difference (AOTD) at 24 months (p=0.5762), variability of height SDS (p=0.627), or time cost to reach a target SDS (p=0.8016) 5.
Regarding administration, the New Genotropin Mark VII Injection Pen was reported as easier to use by 63.16% of dyads compared to previous experiences, with over 65% of dyads reporting no preference or a preference for the new pen 6.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
